Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $86,116.

  • Immuneering's Depreciation & Amortization (CF) fell 4.05% to $86,116 in Q4 2024 from the same period last year, while for Dec 2024 it was $355,807, marking a year-over-year increase of 10.22%. This contributed to the annual value of $355,807 for FY2024, which is 10.22% up from last year.
  • According to the latest figures from Q4 2024, Immuneering's Depreciation & Amortization (CF) is $86,116, which was down 3.18% from $88,949 recorded in Q3 2024.
  • Immuneering's 5-year Depreciation & Amortization (CF) high stood at $90,533 for Q2 2024, and its period low was $5,307 during Q2 2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $78,268 (2023), whereas its average is $77,152.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 468.33% in 2022, then fell by 4.05% in 2024.
  • Quarterly analysis of 5 years shows Immuneering's Depreciation & Amortization (CF) stood at $7,449 in 2020, then skyrocketed by 98.89% to $14,815 in 2021, then surged by 418.81% to $76,862 in 2022, then rose by 16.77% to $89,754 in 2023, then decreased by 4.05% to $86,116 in 2024.
  • Its Depreciation & Amortization (CF) was $86,116 in Q4 2024, compared to $88,949 in Q3 2024 and $90,533 in Q2 2024.